Zoonotic pathogens present persistent diagnostic challenges to clinicians as environmental shifts accelerate viral transmission from rodent reservoirs. Among these threats, hantavirus infections represent an escalating public health concern, impacting more than 200,000 individuals annually worldwide. These enveloped RNA viruses belong to the Hantaviridae family and cause severe systemic illnesses in humans. Because rodents shed viral particles chronically, humans contract infection primarily by inhaling aerosolized excreta. Consequently, healthcare providers must understand the clinical manifestations, pathophysiology, and critical care management of these infections.

Global Epidemiology of Hantavirus Infections

Clinicians broadly categorize hantaviruses into Old World and New World strains based on their geographic distribution and disease manifestations. Old World viruses circulate across Asia, Europe, and parts of Africa, where they cause hemorrhagic fever with renal syndrome. Annually, between 150,000 and 200,000 patients require hospitalization for this condition, with developing regions bearing the highest burden. Case fatality rates range from under 1% to nearly 12%, depending directly on the viral species.

In contrast, New World hantaviruses predominate across North and South America, triggering severe hantavirus cardiopulmonary syndrome. Although fewer individuals contract New World strains, the cardiopulmonary disease carries a high mortality rate approaching 40%. In India and surrounding regions, serological surveys have detected anti-hantavirus antibodies in febrile patients and high-risk occupational cohorts. Furthermore, researchers continue to isolate indigenous rodent-borne strains. Rapid urbanization and changing land use patterns increasingly bring human populations into contact with rodent reservoirs, elevating transmission risk.

Pathophysiological Mechanisms of Endothelial Injury

The hallmark of hantavirus disease centers on widespread capillary leakage without direct cytopathic destruction of the vascular endothelium. Viral glycoproteins bind to beta-3 integrin receptors on host endothelial cells, triggering intense inflammatory signaling cascades. Consequently, infected patients experience severe hypercytokinemia, complement activation, and marked increases in microvascular permeability across multiple vital organs.

This widespread endothelial activation promotes localized platelet consumption, rapidly producing severe thrombocytopenia and abnormal coagulation profiles. As plasma extravasates from the intravascular compartment into surrounding tissues, patients develop significant hemoconcentration, profound hypotension, and systemic hypoperfusion. In renal tissue, capillary leakage causes acute tubular necrosis, retroperitoneal edema, and acute oliguric renal failure. Meanwhile, in pulmonary vascular beds, massive leakage inundates alveolar spaces with protein-rich fluid, triggering fulminant pulmonary edema and cardiogenic shock. Therefore, mitigating microvascular barrier disruption remains the primary therapeutic challenge across all clinical presentations.

Clinical Presentation: HFRS Versus HCPS

Old World strains cause hemorrhagic fever with renal syndrome, which classically progresses through febrile, hypotensive, oliguric, polyuric, and convalescent phases. Patients first experience high fevers, intense headache, abdominal pain, and facial flushing. Subsequently, capillary leakage causes abrupt hypotension, followed by an oliguric phase where acute kidney injury, hyperkalemia, and severe hemorrhages endanger survival. Fortunately, surviving individuals gradually restore renal function during polyuric and convalescent stages.

Conversely, New World strains trigger hantavirus cardiopulmonary syndrome, an aggressively lethal respiratory crisis. Following a non-specific prodrome of fever, myalgia, and gastrointestinal upset, patients develop sudden dyspnea and cough. Within twenty-four hours, non-cardiogenic pulmonary edema and cardiogenic shock emerge. Because both conditions feature leukocytosis, hemoconcentration, and profound thrombocytopenia, clinicians frequently misdiagnose early presentations as dengue, leptospirosis, or severe malaria. Therefore, physicians working in endemic regions must maintain heightened vigilance whenever febrile patients present with sudden thrombocytopenia.

Diagnostic Strategies and Laboratory Confirmation

Accurate diagnosis requires prompt laboratory confirmation because early manifestations overlap extensively with other tropical febrile illnesses. Therefore, laboratory testing must commence immediately whenever clinicians suspect hantavirus disease in patients with compatible rodent exposure histories. Serological testing serves as the primary diagnostic method in clinical hospitals. Specifically, enzyme-linked immunosorbent assays detecting virus-specific immunoglobulin M antibodies provide reliable results, as IgM emerges rapidly during the first week of illness.

In addition, molecular assays via reverse transcription-polymerase chain reaction offer exceptional diagnostic sensitivity during early viremia, detecting viral RNA before antibody titers peak. However, because viremia clears rapidly once severe organ damage manifests, clinicians must collect molecular specimens early in the disease course. Healthcare providers should also recognize typical hematological markers, including profound thrombocytopenia, marked leukocytosis with atypical lymphocytes, and progressive hemoconcentration. This classic triad, particularly when accompanied by acute renal dysfunction or pulmonary infiltrates, warrants urgent confirmatory testing.

Critical Care Management and Infection Control

Currently, regulatory authorities have not approved any specific antiviral therapy or universal vaccine against hantavirus infections. Consequently, meticulous supportive care in an intensive care setting represents the cornerstone of management. Physicians must maintain a delicate fluid balance to avoid worsening pulmonary extravasation. Although hypovolemia requires judicious crystalloid administration, excessive hydration can rapidly precipitate fatal pulmonary edema. Therefore, clinicians frequently institute early vasopressor support to preserve vital organ perfusion without fluid overload.

For patients with severe renal involvement, early continuous renal replacement therapy effectively manages volume overload, corrects refractory electrolyte imbalances, and mitigates uremic complications. In patients presenting with severe cardiopulmonary failure, lung-protective mechanical ventilation and venoarterial extracorporeal membrane oxygenation significantly reduce mortality. While intravenous ribavirin has shown partial efficacy in early hemorrhagic fever with renal syndrome, it offers negligible therapeutic benefit for cardiopulmonary disease. Furthermore, hospitals must enforce rigorous barrier nursing precautions, particularly when managing imported Andes virus infections, which can spread directly between humans.

How do humans contract hantavirus infections from rodent reservoirs?

Humans primarily contract hantaviruses by inhaling microscopic viral particles aerosolized from infected rodent urine, feces, or saliva. This environmental transmission commonly happens during agricultural work or while cleaning enclosed, poorly ventilated buildings. In addition, individuals can occasionally acquire infection through direct contact with contaminated surfaces followed by touching their mucous membranes, or rarely through direct rodent bites. Aside from the Andes virus strain, human-to-human transmission does not occur clinically.

What laboratory findings should raise clinical suspicion for hantavirus disease?

Clinicians should strongly suspect hantavirus disease when a febrile patient exhibits a classical laboratory triad consisting of profound thrombocytopenia, prominent leukocytosis with atypical immunoblasts, and elevated hematocrit indicating hemoconcentration. Furthermore, marked proteinuria, microscopic hematuria, and rapidly rising serum creatinine point toward renal involvement in hemorrhagic fever. When coupled with recent rodent exposure, these hematological derangements warrant immediate serological testing for specific antibodies and prompt molecular evaluation via reverse transcription-polymerase chain reaction.

What are the fundamental principles of managing severe hantavirus disease?

Clinical management focuses primarily on meticulous supportive therapy delivered in an intensive care setting because specific licensed antivirals remain unavailable. Clinicians must practice cautious fluid management to avoid exacerbating capillary leakage into the lungs, frequently utilizing early vasopressors to maintain hemodynamic stability. In addition, patients experiencing acute kidney injury often require timely hemodialysis or continuous renal replacement therapy, whereas individuals with refractory pulmonary failure may require mechanical ventilation or venoarterial extracorporeal membrane oxygenation support.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Uppala PK et al. Hantavirus infections: A growing global health concern. World J Virol. 2026 Sep 25. doi: undefined. PMID: 42781181.
2. Sinto R, Pasaribu AI, Shakinah S, Duindrahajeng BG. Hantavirus Infection: Review of Clinical Management. Acta Med Indones. 2026;58(2):180-192.
3. Pan American Health Organization. Clinical management of hantavirus infection, including Andes virus disease: Interim regional guidance for suspected or confirmed cases. Washington, D.C.: PAHO; 2026.
4. World Health Organization. Hantavirus disease: Outbreak preparedness, surveillance, and clinical care. Geneva: WHO; 2026.